Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2results about How to "Simple preparation route" patented technology

Gelatin particles, methods of making the same, and hemostatic fluid gelatin compositions

PendingCN122251662Aeasy to squeeze outevenly blendedSurgical adhesivesRed blood cellBlood coagulations
The present application provides a gelatin particle and a preparation method thereof, and a hemostatic fluid gelatin composition. The gelatin particle is a cross-linked gelatin particle, and the preparation raw material of the gelatin particle comprises gelatin and a high molecular material containing amino and / or carboxyl; the preparation process of the gelatin particle comprises the steps of forming a gelatin gel from the gelatin and crushing the gelatin gel, wherein the high molecular material is added to mix with the solution of the gelatin or the gelatin gel before or after the formation of the gelatin gel. The gelatin particle and the hemostatic fluid gelatin of the present application can quickly absorb the moisture in the blood after being applied to a bleeding wound, thereby increasing the concentration of red blood cells, blood coagulation factors and the like in the blood, accelerating the endogenous blood coagulation mechanism, and having a good hemostatic effect.
Owner:MEDPRIN REGENERATIVE MEDICAL TECH

4,5,6,7-Tetrahydrothiopheno[2,3-c]pyridine-3-carboxamide compounds, their preparation methods and applications

ActiveCN119161358BNovel structure typeStrong anti-tumor cell proliferation activityOrganic active ingredientsOrganic chemistryDiseaseEpidermal Growth Factor Receptor Kinase
This invention discloses 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide compounds, their preparation methods, and applications, belonging to the field of pharmaceutical technology. Specifically, the general structural formula of the 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide compounds or their pharmaceutically acceptable salts is shown in Formula I, where R1 is defined in the claims and specification. The 4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide compounds or their pharmaceutically acceptable salts provided by this invention, as inhibitors of vascular endothelial growth factor receptor 2 (VEGFR-2) kinase and epidermal growth factor receptor (EGFR) kinase, can be used to prepare drugs for the treatment or prevention of tumors related to VEGFR-2 kinase and EGFR kinase, demonstrating good application value and promising development prospects.
Owner:SHENYANG PHARMA UNIV